

*SARS-CoV-2 detection kits
supplied by ELISABETH PHARMACON*



EliGene[®] COVID19 BASIC A RT

(Cat. No. 90077-RT-A)

EliGene[®] COVID19 BASIC A500 RT

(Cat. No. 90077-RT-A500)

EliGene[®] COVID19 CONFIRM RT

(Cat. No. 90078-RT)

*We recommend the **EliGene[®] SARS-CoV-2 BASIC A RT** and **EliGene[®] SARS-CoV-2 BASIC A500 RT** kits for primary detection.*

*We advise using the **EliGene[®] SARS-CoV-2 CONFIRM RT** for confirmation, specification of unclear samples or in the case of laboratory contamination. Positive results obtained with **EliGene[®] SARS-CoV-2 BASIC A RT** and **EliGene[®] SARS-CoV-2 BASIC A500 RT** need not be confirmed as the specificity of both kits is 100%.*

Common to all kits

- Each kit is a **quadruplex RT-qPCR system**, therefore four targets are simultaneously tested in one tube. The three targets amplify different **SARS-CoV-2** specific sequences, however they all are detected in a single channel.
- This procedure ensures positive results even in case of virus mutation and was chosen with regard to the clear interpretation of results and user comfort. At the same time, such a format contributes to the high sensitivity of a method that was determined by testing (not empirically) to less than 15 copies of RNA added to the sample.
- The most sensitive and specific probes and primers have been selected through multiple testing and comparison for assembly of diagnostic kits of **ELISABETH PHARMACON** for **SARS-CoV-2** detection. In our company we have tested all probes and primers recommended by WHO, there are currently several tens of them available.
- The fourth target in RT-qPCR systems is a unique RNA-based internal amplification control that is added to the lysis step in RNA isolation and thus controls the entire analysis process from RNA isolation, through reverse transcription and qPCR itself. Testing ensured that internal control amplification did not interfere with amplification of three **SARS-CoV-2** targets.
- All specific primers and probes used in the kits are verified on a monthly basis, based on the GenBank database with new known virus sequences, to ensure complete functionality of the kits.
- The multiplex solution for Chlamydia trachomatis or HCV detection kits worldwide has shown that the use of multiplex RT-qPCR systems cannot be associated with a higher risk of laboratory contamination.
- All kits are applicable to RNA isolated from all relevant clinical specimens (nasopharyngeal swabs, saliva, sputum, serum, plasma, faeces) as well as environmental samples (wastewater, etc.).
- All kits use **TaqMan** probe technology and are therefore applicable to devices that work with FAM and HEX / JOE / VIC channels. These are **LightCycler 480** (Roche), **RotorGene-Q** (Qiagen), **CFX96** (Bio-Rad), **QuantStudio** (Life Technologies) and others. If required, passive references for older ABI instruments can be supplied with a 50x ROX solution for addition to the reaction.
- All detection kits are compatible with the **EliGene® Viral RNA / DNA FAST** Isolation Kit (Cat. No. 409100), designed for rapid (15 min) isolation of viral RNA and DNA from swabs, sputum and saliva using specially developed inhibitors removal technology.

Characteristics of individual sets

EliGene® COVID19 BASIC A RT (Cat. No. 90077-RT-A)

EliGene® COVID19 BASIC A500 RT (Cat. No. 90077-RT-A500)

Both kits have the same composition, the **EliGene® SARS-CoV-2 BASIC A RT** is designed to analyze 100 samples, while the **EliGene® SARS-CoV-2 BASIC A500 RT** is designed to analyze 500 samples. Both kits are the same in volume, therefore the 500 sample analysis set saves space and transport costs.

- CE IVD certification (both kits have been registered and have registration number)
- 3 independent targets in the SARS-CoV-2 N gene

EliGene® COVID19 CONFIRM RT (Cat. No. 90078-RT)

- CE IVD certification
- 3 independent targets in the SARS-CoV-2 ORF1ab and E genes